As filed with the Securities and Exchange Commission on March 17, 2017

No. 333-                


 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

___________________

FORM S-1

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

__________________________

 

VIVEVE MEDICAL, INC.

(Exact name of registrant as specified in its charter)

___________________________

 

Delaware

 

3841

 

04-3153858

(State or other jurisdiction of

incorporation or organization)

 

(Primary Standard Industrial

Classification Code Number)

 

(I.R.S. Employer

Identification Number)

 

150 Commercial Street

Sunnyvale, California 94086

Telephone: (408) 530-1900

(Address and telephone number of principal executive offices)

___________________________

 

Scott Durbin

150 Commercial Street

Sunnyvale, California 94086

Telephone: (408) 530-1900

(Name, address and telephone number of agent for service)

___________________________

 

Copies to:

 

 

Mitchell S. Bloom, Esq.

Bradley A. Bugdanowitz, Esq.

Goodwin Procter LLP

Three Embarcadero Center, 28th Floor

San Francisco, California 94111

(415) 733-6000

Jonathan L. Kravetz, Esq.

Megan N. Gates, Esq.

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

One Financial Center

Boston, Massachusetts 02111

(617) 542-6000

 __________________________

 

Approximate date of commencement of proposed sale to the public: As soon as possible after the effective date hereof.

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box.  

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.     Registration No. 333-216187

 

 
 

 

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  

 

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.   

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.  

 

Large accelerated filer     

 

Accelerated filer    

 

 

 

Non-accelerated filer       (Do not check if a smaller reporting company)

 

Smaller reporting company   

 

CALCULATION OF REGISTRATION FEE

             

Title of securities to be registered

Amount
to be
registered
(1)

 

Proposed maximum
offering price
per share

 

Proposed maximum
aggregate offering
price

Amount of
registration
fee
(2)

Common Stock, $0.0001 par value per share

1,197,704

    $4.10  

$4,910,587.41

$569.14

 

(1)

Represents only the additional number of shares being registered and includes 1,125,000 shares of common stock that may be purchased by the underwriters to cover over-allotments, if any. Does not include the securities that the registrant previously registered on the Registration Statement on Form S-1 (File No. 333-216187).

(2)

The registration fee is calculated in accordance with Rule 457(c) under the Securities Act of 1933, as amended, based on the average of the high and low sales prices of the registrant’s common stock as reported by The NASDAQ Capital Market on March 15, 2017. The registrant previously registered securities at an aggregate offering price not to exceed $29,589,412.59 on a registration statement on Form S-1 (File No. 333-216187), which was declared effective by the Securities and Exchange Commission on March 16, 2017. In accordance with Rule 462(b) under the Securities Act, an additional amount of securities having a proposed maximum aggregate offering price of $4,910,587.41 is hereby registered, which includes shares issuable upon the exercise of the underwriters’ over-allotment option.

This registration statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(b) of the Securities Act of 1933, as amended.

 

 
 

 

 

EXPLANATORY NOTE AND INCORPORATION BY REFERENCE

 

Pursuant to Rule 462(b) under the Securities Act of 1933, as amended, Viveve Medical, Inc. is filing this registration statement with the Securities and Exchange Commission, or SEC. This registration statement relates to the public offering of securities contemplated by the registration statement on Form S-1 (File No. 333-216187), which we filed on February 23, 2017, or the Registration Statement, and which the SEC declared effective on March 16, 2017.

 

We are filing this registration statement for the sole purpose of increasing by $4,910,587.41 in maximum aggregate offering price of shares of our common stock to be registered for issuance and sale. The additional securities that are being registered for issuance and sale are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price set forth in the Calculation of Registration Fee table contained in the Registration Statement. The information set forth in the Registration Statement is incorporated by reference in this filing.

 

The required opinions and consents are listed on the exhibit index and filed with this filing.

 

 

 
 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Sunnyvale, State of California, on March 17, 2017.

 

 

VIVEVE MEDICAL, INC.

 

 

 

 

 

 

By:

/s/ Patricia Scheller

 

Date: March 17, 2017

 

Patricia Scheller, Chief Executive Officer

(Principal Executive Officer)

 

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated. 

 

  

Signature

 

Title

 

Date

  

  

  

  

  

  

  

 

 

/s/ Patricia Scheller

  

 

 

Chief Executive Officer and Director

  

  

  

  

  

Patricia Scheller

  

(Principal Executive Officer)  

  

March 17, 2017

  

  

  

  

  

  

  

  

  

/s/ Scott Durbin

  

  

  

Chief Financial Officer

  

  

  

  

  

Scott Durbin

  

(Principal Financial and Accounting Officer)  

  

March 17, 2017

  

  

  

  

  

  

  

  

  

*

  

  

  

  

  

  

  

  

  

Debora Jorn

  

Director

  

March 17, 2017

  

  

  

  

  

  

  

  

  

*

  

  

  

  

  

  

  

  

  

Lori Bush

  

Director

  

March 17, 2017

  

  

  

  

  

  

  

  

  

*

  

  

  

  

  

  

  

  

  

Arlene Morris

  

Director

  

March 17, 2017

  

  

  

  

  

  

 

  

  

*

  

  

  

  

  

  

  

  

 

Daniel Janney

  

Director

  

March 17, 2017

  

  

  

  

  

  

 

  

  

*

  

  

  

  

  

  

  

  

 

Jon Plexico

  

Director

  

March 17, 2017

 

 

 

* By:

 

/s/ Scott Durbin

 

 

 

 

 

Scott Durbin, Attorney-in-Fact

 

 

 

 

 

 
 

 

 

EXHIBIT INDEX

 

Exhibit
Number

 

Description of Exhibit

5.1

 

Opinion of Goodwin Procter LLP

23.1

 

Consent of BPM LLP

23.2

 

Consent of Goodwin Procter LLP (included in Exhibit 5.1)

24.1

Power of Attorney

 

 

*Previously filed on the signature page to the registrant’s registration statement on Form S-1, as amended (File No. 333-216187), originally filed with the Securities and Exchange Commission on February 23, 2017 and incorporated by reference herein.